Expansion of CD4+CD25+FoxP3+ regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 2, 2010, Pages 179-187

  Yoshizawa, Kai ^a   Abe, Hiroshi ^a   Kubo, Yasuhito ^a   Kitahara, Takuya ^a   Aizawa, Ryoichi ^a   Matsuoka, Mika ^a   Aizawa, Yoshio ^a  

^a Jikei University Katsushika Medical Center   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Regulatory T cells

Indexed keywords

CD45RA ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; EARLY CANCER; FEMALE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOCAL THERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 77954354546     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00587.x     Document Type: Article

References (47)

1. Sakaguchi S, Sakaguchi N, Asano M. Immunologic self-tolerance maintained by activated t cells expressing IL-2 receptor α-chains (cd25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-64.
2. Suri-Payer E, Amar AZ, Thornton AM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998, 160:1212-18.
3. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-96.
4. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-8.
5. Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-61.
7. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-6.
8. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-18.
9. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006, 212:272-86.
10. Price JD, Schaumburg J, Sandin C. Induction of a regulatory phenotype in human CD4+ T cells by streptococcal M protein. J Immunol 2005, 175:677-84.
11. Cabrera R, Tu Z, Xu Y. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40:1062-71.
12. Sugimoto K, Ikeda F, Stadanlick J. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003, 38:1437-48.
13. Boettler T, Spangenberg HC, Neumann-Haefelin C. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005, 79:7860-7.
14. Rushbrook SM, Ward SM, Unitt E. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005, 79:7852-9.
15. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002, 107:5-9.
16. Linehan DC, Goedegebuure PS. CD25+ CD4+ regulatory T-cells in cancer. Immunol Res 2005, 32:155-68.
17. Cao M, Cabrera R, Xu Y. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest 2007, 87:582-90.
18. Onizuka S, Tawara I, Shimizu J. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-33.
19. Curtin JF, Candolfi M, Fakhouri TM. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 2008, 3:e1983.
20. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-17.
21. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007, 7:231-7.
22. O'neill EJ, Sundstedt A, Mazza G. Natural and induced regulatory T cells. Ann N Y Acad Sci 2004, 1029:180-92.
23. Ikeda K, Saitoh S, Kobayashi M. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000, 18:252-66.
24. Desmet VJ, Gerber M, Hoofnagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-20.
25. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-36.
26. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual 2002, 6th, edn., Chicago, Springer
27. Ward SM, Fox BC, Brown PJ. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007, 47:316-24.
28. Burton JR, Klarquist J, Im K. Prospective analysis of effector and regulatory CD4(+) T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008, 49:329-38.
29. Li S, Jones KL, Woollard DJ. Defining target antigens for CD25+FOXP3+IFN-γ regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol 2007, 85:197-204.
30. Bolacchi F, Sinistro A, Ciaprini C. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006, 144:188-96.
31. Ebinuma H, Nakamoto N, Li Y. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008, 82:5043-53.
32. Woo EY, Chu CS, Goletz TJ. Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-72.
33. Curiel TJ, Coukos G, Zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-9.
34. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9:4404-8.
35. Liyanage UK, Moore TT, Joo HG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-61.
36. Fu J, Xu D, Liu Z. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-39.
37. Kobayashi N, Hiraoka N, Yamagami W. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007, 13:902-11.
38. Yang XH, Yamagiwa S, Ichida T. Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006, 45:254-62.
39. Ormandy LA, Hillemann T, Wedemeyer H. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-64.
40. Sasaki A, Tanaka F, Mimori K. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008, 34:173-9.
41. Unitt E, Simon M, Marshall A. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005, 41:722-30.
42. Cao X, Cai SF, Fehniger TA. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27:635-46.
43. Chen W, Jin W, Hardegen N. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-86.
44. Roncarolo MG, Gregori S, Battaglia M. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
45. Dong ZZ, Yao DF, Yao M. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008, 7:288-95.
46. Song BC, Chung YH, Kim JA. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002, 94:175-80.
47. Yuen MF, Norris S, Evans LW. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 2002, 37:233-8.